Survival According to Therapy Regimen for Small Intestinal Neuroendocrine Tumors.
delay
diagnosis
metastases
neuroendocrine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Apr 2022
22 Apr 2022
Historique:
received:
16
03
2022
revised:
14
04
2022
accepted:
16
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Scarce data exist for therapy regimens other than somatostatin analogues (SSA) and peptide receptor radiotherapy (PRRT) for siNET. We analyzed real world data for differences in survival according to therapy. Analysis of 145 patients, diagnosed between 1993 and 2018 at a single institution, divided in treatment groups. Group (gr.) 0: no treatment ( 45.5% female, median age 60 years (range, 27-84). A total of 125/145 patients with a resection of the primary tumor. For all patients, 1-year OS (%) was 93.8 (95%-CI: 90-98), 3-year OS = 84.3 (CI: 78-90) and 5-year OS = 77.5 (CI: 70-85). For analysis of survival according to therapy, only stage IV patients (baseline) that received treatment were included. Compared with reference gr. 2 (SSA only), HR for OS was 1.49 ( For stage IV patients in this analysis (limited by low patient numbers in co. 3/4), multimodal treatment did not significantly improve survival over SSA treatment alone. A resection of primary tumor significantly improves survival.
Identifiants
pubmed: 35566487
pii: jcm11092358
doi: 10.3390/jcm11092358
pmc: PMC9104547
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pancreas. 2017 Jul;46(6):715-731
pubmed: 28609357
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Oncologist. 2016 Jun;21(6):671-5
pubmed: 27226359
Ann Surg Oncol. 2020 Oct;27(11):4525-4532
pubmed: 32394299
Eur J Cancer. 2013 Jul;49(11):2565-78
pubmed: 23541566
Neuroendocrinology. 2021;111(10):998-1004
pubmed: 33017827
J Nucl Med. 2017 Sep;58(9):1452-1458
pubmed: 28280220
J Nucl Med. 2011 Dec;52(12):1864-70
pubmed: 22072704
Cancer. 2011 Oct 15;117(20):4617-22
pubmed: 21456005
Cancer. 2020 May 1;126 Suppl 9:2086-2092
pubmed: 32293725
Pancreas. 2017 Jul;46(6):707-714
pubmed: 28609356
J Am Coll Surg. 2020 Apr;230(4):363-370
pubmed: 32032719
Cancer Sci. 2018 Jan;109(1):174-181
pubmed: 29055056
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Neuroendocrinology. 2018;107(4):375-386
pubmed: 30300897
Endocrine. 2019 Nov;66(2):417-424
pubmed: 30875056
Endocrine. 2018 Jun;60(3):499-509
pubmed: 29383678
Medicine (Baltimore). 2021 Sep 17;100(37):e27276
pubmed: 34664885
World J Surg. 2021 Jan;45(1):213-218
pubmed: 32797281
Endocr Relat Cancer. 2016 Mar;23(3):191-9
pubmed: 26743120
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
Ann Surg Oncol. 2020 Aug;27(8):2795-2803
pubmed: 32430752
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Neuroendocrinology. 2019;109(4):333-345
pubmed: 31167197
Swiss Med Wkly. 2020 Jan 15;150:w20176
pubmed: 31940430
J Gastrointest Surg. 2021 Sep;25(9):2368-2376
pubmed: 33403563
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Endocr Relat Cancer. 2022 Feb 07;29(3):163-173
pubmed: 34982042